Memorial Sloan Kettering Cancer Center
The researchers are doing this study to find out whether the combination of zanubrutinib, obinutuzumab, and sonrotoclax (BOSon) is an effective treatment approach for people with mantle cell lymphoma (MCL).
Inclusion Criteria: * Documentation of disease: Patients must have pathologically confirmed MCL at the treating institution * Evaluable disease, stage II-IV o Patients with non-nodal leukemic MCL may enroll even without FDG PET/CT measurable disease; an end-of-treatment BMBx to confirm response is required in such cases * Age ≥ 65 years at screening * If Age \<65, then required to fulfill one of the following criteria disqualifying for autologous transplant (autoHCT): * Comorbid disease(s) such as CAD, heart failure, pulmonary dysfunction, liver, or kidney dysfunction that precludes aut…
PO twice daily of each 28-day cycle
IVPB on days 1, 8, and 15 of cycle 1; and IVPB on day 1 of cycles 2-8
Sonrotoclax will be initiated on C2D1 using the ramp-up schedule